Fund the lab, the analysers and the collection network.
Finance for pathology laboratories, imaging and radiology centres, collection-centre networks and NABL-accreditation upgrades — equipment, fit-out, licences and the working capital the receivables cycle demands.
A volume business, financed accordingly
Diagnostics runs on throughput. Fixed costs — rent, analyser EMI, pathologist and technologist salaries, AMC — are largely invariant, so profitability is a function of test volume against a fixed cost base. Lenders model exactly that: expected tests per day, realisation per test, and the referral base that will generate the flow.
Reagent contracts change the economics substantially. Reagent rental arrangements, where the analyser is placed at low or nil capital cost against a committed reagent offtake, reduce upfront borrowing but lock in per-test costs for years. A capital purchase costs more today and gives you pricing freedom later. Neither is automatically better; the choice should be made on projected volume, and lenders will ask which model you have chosen and why.
Receivables are the operational risk. Corporate tie-ups, insurer panels and hospital contracts pay on 45–120 day cycles while your reagent suppliers and salaries are monthly. A diagnostic file funded only for equipment, with no working capital limit, commonly runs into a cash squeeze within the first two quarters.
Indicative pricing in 2026
Established centres with NABL accreditation and audited financials price well. Greenfield labs are assessed on the promoter's clinical standing.
Public Sector Banks
Tier-1 Private Banks
NBFCs & HFCs
What separates a fundable lab from an unfundable one
An identified referral base, not a hoped-for one
The strongest diagnostic files name their sources: consultants who will refer, hospitals with a signed arrangement, corporate health-check contracts already in discussion. A projection resting on general catchment population and nothing else is the weakest version of this file, and it is the version most applicants bring.
NABL accreditation as a commercial asset
Accreditation is not only a quality mark. Insurer panels, corporate contracts and government scheme empanelment increasingly require it, so it directly determines which revenue you can access. Lenders recognise this and price accredited labs better. Fund the accreditation upgrade as part of the project rather than deferring it.
Working capital sanctioned alongside the equipment
Reagents, consumables and salaries are monthly; panel receivables are not. Sanctioning a cash credit limit at the same time as the equipment loan, sized on the receivable cycle, prevents the squeeze that catches most new centres in their second or third quarter.
Documents required
Incomplete files cause most multi-week delays. We assemble the full set upfront, in the order credit teams read it.
KYC & constitution
- PAN & Aadhaar of all promoters / partners / directors
- Certificate of incorporation, MOA-AOA or partnership deed
- Board resolution or partners' authority letter
- GST registration & trade licence
Professional credentials
- MBBS / BDS / BAMS / BHMS degree & PG certificates
- State Medical Council registration certificate
- Clinical establishment registration
- Practice or employment proof, appointment letters
- Experience certificate showing years post-qualification
Centre & equipment
- Project report with test menu, volume and realisation projections
- Equipment quotations or reagent rental agreement terms
- Clinical establishment registration and lab licence
- AERB licence or application for imaging installations
- Biomedical waste authorisation and pollution consent
- NABL / ISO certification or application status
- Premises lease deed or ownership papers
Related facilities & deep-dive guides
Every facility below is placed through the same 80+ lender panel. The long-form guides carry the working numbers, worked examples and lender-by-lender detail.
Frequently Asked Questions
The questions our advisory desk is asked most often about Diagnostic Centre & Lab Loan.
It turns on volume. Reagent rental minimises capital outlay but locks in per-test reagent pricing for the contract term, which becomes expensive at high throughput. Outright purchase costs more upfront and gives you freedom to negotiate reagents later.
Model both against your realistic first-year and third-year volumes. Lenders will ask which you have chosen, and a clear reasoned answer strengthens the file.
Yes, but the file is assessed on the promoter rather than on the business. A pathologist or radiologist with established practice and an identifiable referral base is a financeable proposition; a purely financial promoter with no clinical anchor is much harder.
Equipment hypothecation, a CGTMSE-backed structure, or collateral all improve the position considerably for a greenfield centre.
Yes, and it is usually essential. A cash credit or overdraft limit sized on your receivable cycle covers the gap between paying for reagents and salaries monthly and collecting from insurer and corporate panels on 45–120 day terms.
See healthcare working capital. Getting it sanctioned alongside the equipment loan, rather than after the squeeze arrives, is much easier.
It helps, on two counts. It signals process quality to the credit team, and more concretely it determines which insurer panels, corporate contracts and government schemes you can access — which is your revenue base.
The cost of the accreditation upgrade can generally be built into the project cost rather than funded separately from your own resources.
Clinical establishment registration, AERB licence for every radiation-emitting installation with prior site layout approval, biomedical waste authorisation, pollution consent and fire clearance.
AERB is the one that dictates your timeline. It cannot be compressed, and most lenders will not disburse for imaging equipment until at least the layout approval is in hand.
Tell us what you need. We'll do the running around.
Share a few details and a CreditCares expert will call you back to map your eligibility and shortlist the right lenders — at no cost.